Larisse Ricardo Gadelha, Maria Juliana Bezerra Costa, João Paulo Alecrim de Abreu, Larissa Paola Rodrigues Venancio, Mary Hellen Fabres-Klein, Raphael Contelli Klein, Jonilson Berlink Lima, Théo Araújo-Santos
{"title":"前列腺素 E2/白三烯 B4 平衡与 COVID-19 不同临床阶段的病毒载量：一项横断面研究。","authors":"Larisse Ricardo Gadelha, Maria Juliana Bezerra Costa, João Paulo Alecrim de Abreu, Larissa Paola Rodrigues Venancio, Mary Hellen Fabres-Klein, Raphael Contelli Klein, Jonilson Berlink Lima, Théo Araújo-Santos","doi":"10.1016/j.prostaglandins.2024.106820","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and leukotriene B<sub>4</sub> (LTB<sub>4</sub>) are eicosanoids involved in modulation of the antiviral immune response. Recent studies have identified increased levels of several eicosanoids in the plasma and bronchoalveolar lavage of patients with coronavirus disease (COVID-19). This study investigated correlations between plasma levels of PGE<sub>2</sub> and LTB<sub>4</sub> and clinical severity of COVID-19.</p></div><div><h3>Methods</h3><p>This cross-sectional study involved non-infected (n = 10) individuals and COVID-19 patients classified as cured (n = 13), oligosymptomatic (n = 29), severe (n = 15) or deceased (n = 11). Levels of D-dimer a, known COVID-19 severity marker, PGE<sub>2</sub> and LTB<sub>4</sub> were measured by ELISAs and data were analysed with respect to viral load.</p></div><div><h3>Results</h3><p>PGE<sub>2</sub> plasma levels were decreased in COVID-19 patients compared to the non-infected group. Changes in PGE<sub>2</sub> and LTB<sub>4</sub> levels did not correlate with any particular clinical presentations of COVID-19. However, LTB<sub>4</sub> was related to decreased SARS-CoV-2 burden in patients, suggesting that only LTB<sub>4</sub> is associated with control of viral load.</p></div><div><h3>Conclusions</h3><p>Our data indicate that PGE<sub>2</sub>/LTB<sub>4</sub> plasma levels are not associated with COVID-19 clinical severity. Hospitalized patients with COVID-19 are treated with corticosteroids, which may influence the observed eicosanoid imbalance. Additional analyses are required to fully understand the participation of PGE<sub>2</sub> receptors in the pathophysiology of COVID-19.</p></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"172 ","pages":"Article 106820"},"PeriodicalIF":2.5000,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prostaglandin E2/Leukotriene B4 balance and viral load in distinct clinical stages of COVID-19: A cross-sectional study\",\"authors\":\"Larisse Ricardo Gadelha, Maria Juliana Bezerra Costa, João Paulo Alecrim de Abreu, Larissa Paola Rodrigues Venancio, Mary Hellen Fabres-Klein, Raphael Contelli Klein, Jonilson Berlink Lima, Théo Araújo-Santos\",\"doi\":\"10.1016/j.prostaglandins.2024.106820\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and leukotriene B<sub>4</sub> (LTB<sub>4</sub>) are eicosanoids involved in modulation of the antiviral immune response. Recent studies have identified increased levels of several eicosanoids in the plasma and bronchoalveolar lavage of patients with coronavirus disease (COVID-19). This study investigated correlations between plasma levels of PGE<sub>2</sub> and LTB<sub>4</sub> and clinical severity of COVID-19.</p></div><div><h3>Methods</h3><p>This cross-sectional study involved non-infected (n = 10) individuals and COVID-19 patients classified as cured (n = 13), oligosymptomatic (n = 29), severe (n = 15) or deceased (n = 11). Levels of D-dimer a, known COVID-19 severity marker, PGE<sub>2</sub> and LTB<sub>4</sub> were measured by ELISAs and data were analysed with respect to viral load.</p></div><div><h3>Results</h3><p>PGE<sub>2</sub> plasma levels were decreased in COVID-19 patients compared to the non-infected group. Changes in PGE<sub>2</sub> and LTB<sub>4</sub> levels did not correlate with any particular clinical presentations of COVID-19. However, LTB<sub>4</sub> was related to decreased SARS-CoV-2 burden in patients, suggesting that only LTB<sub>4</sub> is associated with control of viral load.</p></div><div><h3>Conclusions</h3><p>Our data indicate that PGE<sub>2</sub>/LTB<sub>4</sub> plasma levels are not associated with COVID-19 clinical severity. Hospitalized patients with COVID-19 are treated with corticosteroids, which may influence the observed eicosanoid imbalance. Additional analyses are required to fully understand the participation of PGE<sub>2</sub> receptors in the pathophysiology of COVID-19.</p></div>\",\"PeriodicalId\":21161,\"journal\":{\"name\":\"Prostaglandins & other lipid mediators\",\"volume\":\"172 \",\"pages\":\"Article 106820\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-02-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostaglandins & other lipid mediators\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1098882324000145\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins & other lipid mediators","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1098882324000145","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Prostaglandin E2/Leukotriene B4 balance and viral load in distinct clinical stages of COVID-19: A cross-sectional study
Background
Prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are eicosanoids involved in modulation of the antiviral immune response. Recent studies have identified increased levels of several eicosanoids in the plasma and bronchoalveolar lavage of patients with coronavirus disease (COVID-19). This study investigated correlations between plasma levels of PGE2 and LTB4 and clinical severity of COVID-19.
Methods
This cross-sectional study involved non-infected (n = 10) individuals and COVID-19 patients classified as cured (n = 13), oligosymptomatic (n = 29), severe (n = 15) or deceased (n = 11). Levels of D-dimer a, known COVID-19 severity marker, PGE2 and LTB4 were measured by ELISAs and data were analysed with respect to viral load.
Results
PGE2 plasma levels were decreased in COVID-19 patients compared to the non-infected group. Changes in PGE2 and LTB4 levels did not correlate with any particular clinical presentations of COVID-19. However, LTB4 was related to decreased SARS-CoV-2 burden in patients, suggesting that only LTB4 is associated with control of viral load.
Conclusions
Our data indicate that PGE2/LTB4 plasma levels are not associated with COVID-19 clinical severity. Hospitalized patients with COVID-19 are treated with corticosteroids, which may influence the observed eicosanoid imbalance. Additional analyses are required to fully understand the participation of PGE2 receptors in the pathophysiology of COVID-19.
期刊介绍：
Prostaglandins & Other Lipid Mediators is the original and foremost journal dealing with prostaglandins and related lipid mediator substances. It includes basic and clinical studies related to the pharmacology, physiology, pathology and biochemistry of lipid mediators.
Prostaglandins & Other Lipid Mediators invites reports of original research, mini-reviews, reviews, and methods articles in the basic and clinical aspects of all areas of lipid mediator research: cell biology, developmental biology, genetics, molecular biology, chemistry, biochemistry, physiology, pharmacology, endocrinology, biology, the medical sciences, and epidemiology.
Prostaglandins & Other Lipid Mediators also accepts proposals for special issue topics. The Editors will make every effort to advise authors of the decision on the submitted manuscript within 3-4 weeks of receipt.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
